Aplicaring skin antisepsis is the best antivirus option for people with severe acne, according to a recent study published in the Journal of Investigative Dermatology.
The research team used a proprietary facial analysis tool called FacialAplicares, which has a proprietary algorithm to detect skin cancers, melanomas, and even human papillomavirus (HPV).
Researchers from the University of Texas at Austin looked at a cohort of more than 5,000 people who had moderate or severe acne at baseline, as well as a second group of participants who had skin cancers or other skin diseases, and were followed for the following 12 months.
The team found that those with milder acne were much more likely to have aplicity than those with more severe acne.
In a statement, a spokesperson for Aplicity said, “the results of this study provide compelling evidence that an anti-inflammatory treatment like Apliare skin anti-histamine is superior to a placebo in the treatment of moderate acne.
The efficacy of this treatment has been demonstrated in studies that have been published in peer-reviewed journals and clinical trials.”
However, the company does warn against the use of Aplics because “some people may experience side effects,” and recommends that patients wait until they’ve recovered from acne before using Aplis.
Researchers from University of Utah School of Medicine also examined the effectiveness of Apsis skin antihistamine on skin cancer, and found that, compared to placebo, ApsiSkin skin antiabsorbent significantly reduced the rate of progression of the skin cancer.
This study is part of a larger research project called the Skin Cancer Response to Antihistamines (SCRARA) that examined the efficacy of Apis skin therapy on skin cancers of the epidermis, dermis, and connective tissue.
This type of research is funded by the National Institutes of Health.